SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing high trading volume and active community sentiment as investors focus on the company's QNX software as a foundational element for physical AI and robotics, while management's upcoming investor conference appearances and share buyback program fuel speculation about future growth. The community remains highly bullish, citing recent institutional accumulation and the potential for a long-term turnaround as BlackBerry expands its role in mission-critical embedded systems.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending as investors weigh an earnings beat against concerns over a sluggish housing market and reduced consumer spending. The community is actively debating the stock's future, with many highlighting its role as a key barometer for the broader economy while tracking its potential for a reversal.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending following a strong quarterly earnings report featuring revenue growth that beat analyst expectations and raised full-year guidance, fueled by accelerating enterprise adoption of its AI-powered features. Community sentiment is heavily focused on a potential short squeeze, with investors highlighting significant short interest and arguing that the companys strong net dollar retention and essential role in design workflows prove its long-term value despite broader market concerns about AI competition.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is currently trending as investors digest their recent earnings report, with the community actively debating the company's long-term commercial potential against significant operational expenses. Despite a volatile share price, supporters are pointing to raised revenue guidance, key defense contract wins, and a robust cash position as reasons for bullish conviction.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors anticipate a major data readout from an oral plenary presentation at the upcoming AUA Annual Meeting. The community is heavily focused on the extended follow-up data for CAN-2409 in prostate cancer, with widespread discussion regarding its potential to serve as a practice-changing therapy, the durability of its survival benefit, and the possibility of a premium acquisition by Big Pharma.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is currently trending following a strong quarterly earnings report that featured a revenue and EPS beat alongside a raised outlook for the semiconductor equipment market, signaling sustained growth driven by AI infrastructure demand. The community is actively discussing the company's upgraded price targets from multiple major analyst firms and debating the durability of the AI supercycle versus potential valuation concerns.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently surging due to a combination of strong institutional buy-in ahead of upcoming earnings and recent reports regarding the approval of H200 chip sales to major Chinese technology firms. The community remains heavily divided between bullish investors who view the company's AI-driven growth as a fundamental long-term opportunity and skeptical voices who fear the stock's massive market capitalization may indicate a speculative bubble that is vulnerable to a post-earnings sell-the-news event.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is trending as investors aggressively build positions ahead of an anticipated SpaceX IPO, with the community highlighting the company's role as a key hardware supplier for orbital infrastructure and defense programs. Traders are closely monitoring the stock's volume and technical breakouts, debating whether the current momentum represents a long-term re-rating or another volatile pump-and-dump cycle.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

Boost Run Inc. is drawing significant community interest following its recent de-SPAC transition and a strategic partnership with CDW, which investors are linking to broader momentum in AI infrastructure and "neocloud" providers. While some market participants are debating the stock's volatility and potential for a short squeeze given its tight share float, many are focused on its long-term potential as a smaller-cap AI data center player.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is rallying following a strategic $100 million investment from Winklevoss Capital, which has fueled community speculation about a potential short squeeze given the stock's elevated short interest. Investors are closely weighing this capital infusion and stronger-than-expected earnings against ongoing concerns regarding the company's long-term path to profitability and recent legal challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 737,720...

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.

Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average   - What's Next?

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 50-Day Moving Average - Here's What Happened...

Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving Average - Time to Sell?

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above Fifty Day Moving Average - Should You Sell...

Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Wall Street Zen raised shares of Spero Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Sunday...

Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.73 EPS

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts...

Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to "Hold"

Wall Street Zen lowered shares of Spero Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday...

Spero Therapeutics (SPRO) Expected to Announce Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-spero-therapeutics-inc-stock...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Decline in Short Interest

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 574,027 shares, a...

Short Interest in Spero Therapeutics, Inc. (NASDAQ:SPRO) Declines By 24.0%

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling...

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Current Price	$2.76
Prev Close	$2.44
Open	$2.44
Dividend Yield	0.00%
50-Day Moving Average	$2.55
Beta	0.84
Avg. Volume	459,998.08
PE Ratio	11.33

52-Week High	$3.22
52-Week Low	$0.6303
Market Capitalization	$159.81M
EPS (Annual)	$0.1452
Price to Book	3.02
Revenue Per Employee	$2.38M

SPRO
Spero Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SPRO News

SPROSpero Therapeutics Inc